Selective prescribing of spasmolytics

Annals of Pharmacotherapy

Volumn 34, Issue 6, 2000, Pages 716-720

  Movig, Kris L L ^a,b   Egberts, Antoine C G ^c   Lenderink, Albert W ^c   Leufkens, Hubert G M ^b  

^a GGZ Midden Brabant   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Utrecht Inst Pharmaceutical Sci ^*

Author keywords

Selective prescribing; Tolterodine

Indexed keywords

EMEPRONIUM; FLAVOXATE; OXYBUTYNIN; PSYCHOTROPIC AGENT; SPASMOLYTIC AGENT; TOLTERODINE;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0034130076     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19267     Document Type: Article

References (13)

1. Leufkens HGM, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994;46(suppl 1):433-7.
2. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
3. WHO Collaborating Centre for Drug Statistics Methodology. Olso, Norway: World Health Organization, 1998.
4. SPSS for Windows 9.0.0. SPSS, 1989-1999.
5. Leufkens HGM, Urquhart J, Stricker BHCH, Bakker A, Petri H. Channeling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastro-intestinal problems. J Epidemiol Commun Hlth 1992;46:428-32.
6. Petri H, Urquhart J, Herings R, Bakker A. Characteristics of patients prescribed three different inhalational beta-2 agonists: an example of the channeling phenomenon. Post Marketing Surveillance 1991;5:57-66.
7. Petri H, Heerdink R, Leufkens HGM, Kessels F, Urquhart J. Channeling of antidepressant drugs to patients with cardiovascular disease. Post Marketing Surveillance 1991;5:159-67.
8. Egberts ACG, Lenderink AW, de Koning GHP, Leufkens HGM. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Psychopharmacol 1997;17:149-55.
9. de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Meché FGA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-6.
10. Nilvebrant L, Hallén B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36.
11. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1993;6:243-62.
12. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993;342:658-61.
13. Leufkens HGM, Urquhart J. Prescriber profile and postmarketing surveillance (letter). Lancet 1993;342:1178.